UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934

For the month of February 2019

Commission File Number: 001-37643

KITOV PHARMA LTD.
(Translation of registrant's name into English)

One Azrieli Center, Round Tower,
Tel Aviv 6701101, Israel
(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____

Kitov Pharma Ltd. (the “Company” or the “Registrant”) is announcing that it has made available an updated Company Presentation on its website. A copy of the updated Company Presentation is attached hereto as Exhibit 99.1 and may be viewed at the Company’s website at www.kitovpharma.com.

Exhibit 99.1	Kitov Pharma Company Presentation – February 2019

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

KITOV PHARMA LTD.

February 11, 2019

By: /s/ Isaac Israel
Isaac Israel
CEO and Director

Exhibit 99.1

Forward-Looking Statements and Kitov's Safe Harbor Statement

This presentation is not a prospectus or offer of securities for subscription or sale in any jurisdiction.

Certain statements in this presentation are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other applicable securities laws. Forward-looking statements can be identified by the use of forward-looking words such as "believe", "expect", "intend", "plan", "may", "should", "could", "might", "seek", "target", "will", "project", "forecast", "continue" or "anticipate" or their negatives or variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical matters. You should not place undue reliance on these forward-looking statements, which are not guarantees of future performance. Forward-looking statements reflect our current views, expectations, beliefs or intentions with respect to future events, and are subject to a number of assumptions, involve known and unknown risks, many of which are beyond our control, as well as uncertainties and other factors that may cause our actual results, performance or achievements to be significantly different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause or contribute to such differences include, among others, risks relating to: the fact that drug development and commercialization involves a lengthy and expensive process with uncertain outcomes; our ability to successfully acquire, develop or commercialize our pharmaceutical products; the expense, length, progress and results of any clinical trials; the lack of sufficient funding to finance the clinical trials; the impact of any changes in regulation and legislation that could affect the pharmaceutical industry; the difficulty in receiving the regulatory approvals necessary in order to commercialize our products; the difficulty of predicting actions of the U.S. Food and Drug Administration or any other applicable regulator of pharmaceutical products; the regulatory environment and changes in the health policies and regimes in the countries in which we operate; the uncertainty surrounding the actual market reception to our pharmaceutical products once cleared for marketing in a particular market; the introduction of competing products; patents attained by competitors; dependence on the effectiveness of our patents and other protections for innovative products; our ability to obtain, maintain and defend issued patents with protective claims; the commencement of any patent interference or infringement action; our ability to prevail, obtain a favorable decision or recover damages in any such action; and the exposure to litigation, including patent litigation, and/or regulatory actions; the uncertainty surrounding an investigation by the Israel Securities Authority into our historical public disclosures and the potential impact of such investigation on the trading of our securities or on our clinical, commercial and other business relationships, or on receiving the regulatory approvals necessary in order to commercialize our products, and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2017 and in our other filings with the SEC, including our cautionary discussion of risks and uncertainties under "Risk Factors" in our Registration Statements and Annual Reports. These are factors that we believe could cause our actual results to differ materially from expected results. Other factors besides those we have listed could also adversely affect us. Any forward-looking statement in this press release speaks only as of the date which it is made. We disclaim any intention or obligation to publicly update or revise any forward-looking statement, or other information contained herein, whether as a result of new information, future events or otherwise, except as required by applicable law. You are advised, however, to consult any additional disclosures we make in our reports to the SEC, which are available on the SEC's website, http://www.sec.gov.

Company Profile

Innovative Pharmaceutical Company
Leveraging Deep Regulatory and Drug Development Expertise

DIVERSE PIPELINE ADDRESSING LARGE MARKETS

- NT-219 - small molecule designed to overcome cancer drug resistance
- Consensi™ - approved by FDA to treat osteoarthritic pain and hypertension
- Consensi™ is licensed for marketing in the U.S., China and S. Korea

PROVEN TEAM

- Management team with proven track record in drug development, NDA submissions and FDA approvals
- Consensi™ manufacturing and CMC activity partnered with Dexcel Pharma, Israel's largest private pharmaceutical company

COMPELLING VALUE

- Publicly traded on TASE 2013; IPO on NASDAQ in November 2015
- Tickers: KTOV (ADSs); KTOVW (Warrants)
- Cash on hand (as of January 2019): ~$13M
- Market Cap: $24M*
- Issued & outstanding capital equivalent to 19.5 million ADSs

* As of February 5th, 2019

Experienced Management

Paul Waymack, M.D., Sc.D.
Chairman of the Board & Chief Medical Officer
Former FDA medical officer

Isaac Israel
Chief Executive Officer
Former CEO of BeeContact (TASE: BCNT), NextGen Biomed (TASE: NXGN)

Gil Efron
Deputy CEO and Chief Financial Officer
Formerly at Kamada (NASDAQ: KMDA)

Gil Ben-Menachem, Ph.D., MBA
Vice President, Business Development
Formerly at Paramount, Teva, Dexcel, NIH

Hadas Reuveni, Ph.D.
Founder & Chief Technology Officer - TyrNovo
Formerly at Keryx (NASDAQ: KERX)

FDA KAMADA TEVA KERYX NATIONAL INSTITUTES OF HEALTH Dexcel pharma

Milestone Schedule

Milestone	Expected Date
NT-219 - Complete pre-clinical development plan	H1/2019
NT-219 - Submit IND application to FDA	H2/2019
NT-219 - Collaboration agreement with potential strategic partner	H2/2019
NT-219 - Initiation of a clinical study	H2/2019
Consensi™ - Complete preparation for U.S. launch	H2/2019
In license/acquire additional drug candidate	2019

Consensi™

About Consensi™

Full U.S. Prescribing Information is available at: www.consensi.com

Fixed dose combination of **Celecoxib**, a COX-2 selective NSAID *(the active ingredient in Pfizer's Celebrex®)*

+

Amlodipine, a blood pressure-lowering agent (a calcium channel blocker) *(the active ingredient in Pfizer's Norvasc®)*

Simultaneous treatment of osteoarthritic pain and hypertension

- Approved for marketing by U.S. FDA on May 31, 2018
- Clinical data showed Consensi™ was more effective at lowering blood pressure than amlodipine alone
- Clinical data also demonstrated beneficial renal function measures
- Formulated with 200 mg celecoxib and three different dosages (2.5, 5, 10 mg) of amlodipine
- Manufactured by Dexcel Pharma – Israel's largest private pharmaceutical company

**Celebrex® is a registered trademark of G.D. Searle LLC (a subsidiary of Pfizer Inc.).*
Norvasc® is a registered trademark of Pfizer Inc.

Consensi™ U.S. Target Markets

Consensi™ targets osteoarthritic patients currently treated with NSAIDs (celecoxib as well as others) who also suffer from existing or newly diagnosed hypertension

ARTHRITIS PREVALENCE*

- More than 50 million adults in the U.S. have doctor-diagnosed osteoarthritis
- 67 million people are expected to have doctor-diagnosed osteoarthritis by 2030



HYPERTENSION PREVALENCE**

- 29% of U.S. adults older than 18
- 65% of U.S. adults older than 60

COMORBIDITIES

- 44% of adults with high blood pressure have osteoarthritis**

** Arthritis Foundation: http://www.arthritis.org/ ** Hypertension Among Adults in the United States: National Health and Nutrition Examination Survey, 2011–2012*

Consensi™ Benefits All Stakeholders

Consensi™ is the only NSAID whose labeling indicates reduction of blood pressure and consequent risk reduction of heart attack, stroke and death



Consensi™ Commercialization



NT-219

NT-219: Overcoming Cancer Drug Resistance

- A novel small molecule that prevents, reverses, and delays resistance to anti-cancer drugs
- Demonstrated outstanding efficacy in patient-derived xenograft (PDX) models
- Favorable response received from FDA in pre-IND meeting
- Ongoing preclinical work; IND expected in 2019
- Initial dose escalation clinical study in combination with approved oncology drugs expected H2/2019
- Long-term strategy to develop NT-219, in combination with other oncology drugs for additional indications, either alone or in collaboration with strategic partners

NT-219: Mechanism of Action

- Anti-cancer drugs induce activation of two feedback pathways, STAT3 and IRS, both known modulators of tumor survival, metastasis and drug resistance
- NT-219 binds directly to STAT3 and IRS1/2, and enhances the tumors' response to the approved drugs
- STAT3 is known to be active in the immune evasion mechanism of the tumor
- Short exposure of cancerous cells to NT-219 was sufficient to trigger irreversible shutdown of these pathways, resulting in a long-term anti-cancer effect



Results in PDX Models



NT-219 Prevents Acquired Resistance to EGFR Inhibitor (Tarceva®) in Head and Neck Cancer



NT-219 Reverses Existing Resistance to Tarceva® in Head and Neck Tumors



NT-219 Delays Recurrence of Tumors of Head and Neck with Cetuximab



NT-219 Prevents Acquired Resistance to MEK Inhibitor (Mekinist®) in Mutated-BRAF Anaplastic Thyroid Cancer

Results in Immuno-Oncology PDX Model in Combination with Keytruda®

NT-219 Converts Non-Responding Tumors to Keytruda® to Responders in Humanized PDX of Esophagus Cancer



Double autologous model - tumors and PBMCs of the same patient

Efficacy in Pancreatic Cancer Models

NT-219 Converts Non-Responding Tumors to Responders
to Gemcitabine in 4/4 PDX Models of Pancreatic Cancer



Summary of Demonstrated Efficacy

NT-219 will be developed in combination with approved oncology drugs to increase efficacy, expand target population, and extend treatment duration

	TYPE	DRUG (TRADE NAME)	CANCER TYPE	OWNED BY
Targeted Drugs	Antibody	Cetuximab (Erbitux®)	Head and Neck	Lilly
		Cetuximab (Erbitux®) + FOLFOX/FOLFIRI	Colon (wt KRAS)	
	Kinase Inhibitors	Erlotinib (Tarceva®)	Head and Neck	Roche / Astellas
		Afatinib (Giotrif®)	Head and Neck	Boehringer Ingelheim
		Osimertinib (Tagrisso®)	Lung	AstraZeneca
		Vemurafenib (Zelboraf®)	Melanoma	Roche
		Trametinib (Mekinist®)	Thyroid	Novartis
		Everolimus (Afinitor®)	Uterine Adenosarcoma	
Chemotherapy		Gemcitabine (Gemzar®)	Pancreatic	Lilly
		5FU, Oxaliplatin (FOLFOX)	Colon	Sanofi
		Docetaxel (Taxotere®)	Prostate	
Immunotherapy	Antibody	Pembrolizumab (Keytruda®)	Melanoma, NSCLC, Head and Neck	Merck

NT-219 Development Plan



Summary

Proven management team	• Management team with track record in drug development and regulatory expertise
Balanced and diverse pipeline	• Consensi™ approved for marketing in the U.S. by FDA, licensed in the U.S., China and S. Korea • NT-219 IND expected in 2019
Large market potential	• Consensi™ addresses large target population • NT-219 has blockbuster potential in multiple malignancies
Strong IP portfolio	• Consensi™ is U.S. patent protected through 2030 • NT-219 composition patent was granted, combination patents are pending

Company Headquarters
One Azrieli Center
Round Tower, Floor 19
132 Begin Road
Tel Aviv 670110 Israel

US Medical Research Office
1615 Suter's Lane NW
Washington DC 20007

Contact Us
Email: IR@kitovpharma.com
www.kitovpharma.com
Tel. 972 3 9333121

Appendix A - Consensi™ Clinical Data

Medical Rationale

Celecoxib (the active ingredient in Pfizer's Celebrex®)

- The only widely prescribed selective COX-2 NSAID approved in the U.S. (unlike non-selective NSAIDs, celecoxib carries limited gastrointestinal risks)
- Since 2005, has an FDA-mandated "black box" label warning of increased cardiovascular risks
- According to FDA, cardiovascular risks can occur as early as the first few weeks of using an NSAID, and may increase with longer use

WARNING: CARDIOVASCULAR AND GASTROINTESTINAL RISKS
See full prescribing information for complete boxed warning

Cardiovascular Risk

- **CELEBREX, may cause an increased risk of serious cardiovascular thrombotic events, myocardial infarction, and stroke, which can be fatal. All NSAIDs may have a similar risk. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. *(5.1,14.7)***

Amlodipine (the active ingredient in Pfizer's Norvasc®)

- Calcium channel blocker; anti-hypertensive
- Unlike other blood pressure-lowering drug groups – such as diuretics, ACE inhibitors, and angiotensin II receptor antagonists – calcium channel blockers do not cause deterioration of renal function, including possible acute renal failure*

** The FDA Safety Information and Adverse Event Reporting Program; http://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm270998.htm*

Consensi™ Phase III Trial Design



Primary endpoint

Demonstrate that the reduction in blood pressure in the Consensi™ arm is **at least 50% of the reduction in the amlodipine arm**

Measurement of pain was not required by FDA

Consensi™ Phase III Trial Results



Consensi™ demonstrated even better BP reduction than same amount of amlodipine given without celecoxib

** Error bars – standard error of mean*

- Primary efficacy endpoint was successfully achieved (P=0.001)
- Demonstrated 2.5x better blood pressure reduction than FDA requirement (50% of amlodipine arm)
- Demonstrated consistent reduction in all measures of blood pressure
- Observed beneficial renal functions:

Measure	Consensi™	Amlodipine
Creatinine plasma level reduction	-3.22 µmol/L	-2.55 µmol/L
Peripheral edema (% patients)	8.2%	15.6%

- Additional Phase III/IV clinical trial to scientifically validate the renal benefits (not required for NDA submission) was completed. Topline results were announced in October, 2017

Consensi™ Phase III/IV Clinical Trial Design



Primary endpoint

Demonstrate that the reduction in blood pressure in the Consensi™ arm is **at least 50% of the reduction in the amlodipine arm**

Secondary endpoints

Improvements of renal function measurements

Consensi™ Phase III/IV Clinical Trial Results

- Primary efficacy endpoint successfully met (p=0.019), thus Phase III trial results validated
- Statistically significant reduction of serum creatinine observed vs. baseline
- Consensi™ enhanced the creatinine reduction by an average of 102% vs. amlodipine alone
- Consensi™ demonstrated systolic blood-pressure reduction comparable to amlodipine



	Consensi™ (n=48)	Amlodipine (n=49)
Creatinine plasma level reduction	-3.48 µmol/L	-1.72 µmol/L
p-value	0.0005	0.075